(Report ID: 150053) Many drug interactions and side effects can not be detected until the drugs have been used by millions of people, and for a long time. Large, long-term drug safety studies are ideal to discover these real-world drug outcomes. For the first time, eHealthMe enables health professionals and patients to conduct these studies for their drugs. Click here to check your drugs now, in a whole new way. As of Nov, 21, 2008, eHealthMe analyzes 10,180,646 drug interactions and side effects of 21,667 FDA-approved drugs from 1977 to the present. Results on Nov, 21, 2008: 18 relevant incidents
Note:
- The incidents can not include all actual occurrences
- Data of 2008 is not complete
DISCLAIMER: All adverse drug reaction material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk. Basic information:
| Report ID | Date of submission | Patient age | Patient gender |
| 150053 | Jun, 22, 2006 | 74 | Female |
List of drugs the patient takes:
| Drug |
Detrol La |
Miacalcin |
Evista |
List of drug interactions, adverse side effects / events the patient has:
| Name |
Cardiac Disorder |
Depression |
Drug Effect Decreased |
Drug Ineffective |
Dry Mouth |
Parkinson's Disease |
Therapy Regimen Changed |
Ventricular Dysfunction |
Results from eHealthMe: 18 relevent incidents1) Comparison with the patient's adverse outcomes:
| Name | Count (% of total reports) |
Cardiac Disorder | 1 (5.56%) |
Depression | 1 (5.56%) |
Drug Effect Decreased | 3 (16.67%) |
Drug Ineffective | 2 (11.11%) |
Dry Mouth | 1 (5.56%) |
Parkinson's Disease | 1 (5.56%) |
Therapy Regimen Changed | 1 (5.56%) |
Ventricular Dysfunction | 1 (5.56%) |
2) Top drug interactions, adverse side effects reported for the past 12 months:
3) Top co-used drugs drugs reported for the past 12 months:
4) Top drug interactions, adverse side effects reported of all time:Death: 0 Cancer: 0
| Name | Count (% of total reports) |
1 | Myocardial Infarction | 5 (27.78%) |
2 | Eye Infection | 3 (16.67%) |
3 | Nasal Congestion | 3 (16.67%) |
4 | Condition Aggravated | 3 (16.67%) |
5 | Hearing Impaired | 3 (16.67%) |
6 | Blood Cholesterol Increased | 3 (16.67%) |
7 | Drug Effect Decreased | 3 (16.67%) |
8 | Fall | 3 (16.67%) |
9 | Rib Fracture | 3 (16.67%) |
10 | Pleural Effusion | 3 (16.67%) |
5) Top co-used drugs drugs reported of all time:
| Name | Count |
1 | Aciphex | 6 |
2 | Pravachol | 4 |
3 | Vioxx | 4 |
4 | Paxil | 3 |
5 | Norvasc | 3 |
6 | Nexium | 3 |
7 | Metoprolol Tartrate | 3 |
8 | Robaxin | 3 |
9 | Ambien | 3 |
10 | Atacand | 3 |
Want to have a risk analysis report like this for your drugs? Click here. ADVERTISEMENT
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Recent drug risk analysis reports:
Vicodin Es (Abbott) - 750MG;7.5MG for Toothaches (Nov, 21, 2008)
|
Vicodin Es (Abbott) - 750MG;7.5MG for Toothaches (Nov, 21, 2008)
|
Lyrica (Pfizer) - 100MG for Back Pain - Low (Nov, 21, 2008)
|
Sodium Bicarbonate (Hospira) - 0.9MEQ... for Heartburn (Nov, 21, 2008)
|
Side effects comparison of Lipitor (Pfizer) - EQ 20MG BASE (Nov, 21, 2008)
|
Lipitor (Pfizer) - EQ 20MG BASE for Cholesterol (Nov, 21, 2008)
|
Lipitor (Pfizer) - EQ 20MG BASE for Cholesterol (Nov, 21, 2008)
|
Digoxin (Roxane) - 0.05MG/ML for Heart Condition (Nov, 21, 2008)
|
Digoxin (Roxane) - 0.05MG/ML for Heart Condition (Nov, 21, 2008)
|
Glycopyrrolate for Hyperhidrosis (Nov, 21, 2008)
|
|
|
|
 |
|
How to use the report?
Bring a copy of this report to a doctor's appointment to ensure drug risks are fully discussed and understood, in the process of risk and benefit assessment.
|
 |
|
ADVERTISEMENT
|
|